Search icon

PHARMACOUSTICS TECHNOLOGIES LLC

Company Details

Name: PHARMACOUSTICS TECHNOLOGIES LLC
Jurisdiction: New York
Legal type: DOMESTIC LIMITED LIABILITY COMPANY
Status: Active
Date of registration: 24 Nov 2010 (15 years ago)
Entity Number: 4023689
ZIP code: 13676
County: St. Lawrence
Place of Formation: New York
Address: 6 CIRCLE DR., POTSDAM, NY, United States, 13676

Agent

Name Role Address
CETIN CETINKAYA Agent 6 CIRCLE DR., POTSDAM, NY, 13676

DOS Process Agent

Name Role Address
C/O CETIN CETINKAYA DOS Process Agent 6 CIRCLE DR., POTSDAM, NY, United States, 13676

U.S. Small Business Administration Profile

The U.S. Small Business Administration (SBA) helps Americans start, grow, and build resilient businesses.

Note: SBA was created in 1953 as an independent agency of the federal government to aid, counsel, assist and protect the interests of small business concerns; preserve free competitive enterprise; and maintain and strengthen the overall economy of our nation. SBA reviews Congressional and testifies on behalf of small businesses. It assesses the impact of regulatory burden on small businesses.

Phone Number:
E-mail Address:
Contact Person:
CETIN CETINKAYA
User ID:
P2433057

Unique Entity ID

A UEI is a government-provided number, like a tax ID number, that’s used to identify businesses eligible for federal grants, awards and contracts.

Note: In April 2022, the federal government replaced its old identifier of choice, the Data Universal Numbering System (DUNS) number, with a government-issued UEI. Now all the federal government’s Integrated Award Environment systems use UEI numbers instead of DUNS numbers. So any entity doing business with the federal government must register for a UEI.

Unique Entity ID:
Q3MXF165G6H9
CAGE Code:
8GZS5
UEI Expiration Date:
2025-12-26

Business Information

Activation Date:
2024-12-30
Initial Registration Date:
2020-02-04

History

Start date End date Type Value
2010-11-24 2025-04-21 Address 6 CIRCLE DR., POTSDAM, NY, 13676, USA (Type of address: Registered Agent)
2010-11-24 2025-04-21 Address 6 CIRCLE DR., POTSDAM, NY, 13676, USA (Type of address: Service of Process)

Filings

Filing Number Date Filed Type Effective Date
250421003064 2025-04-21 BIENNIAL STATEMENT 2025-04-21
230110002815 2023-01-10 BIENNIAL STATEMENT 2022-11-01
201105061393 2020-11-05 BIENNIAL STATEMENT 2020-11-01
181107006472 2018-11-07 BIENNIAL STATEMENT 2018-11-01
141110006732 2014-11-10 BIENNIAL STATEMENT 2014-11-01

USAspending Awards / Financial Assistance

Date:
2024-08-30
Awarding Agency Name:
National Science Foundation
Transaction Description:
STTR PHASE II: ULTRASONIC PRODUCT RELEASE-TESTING EQUIPMENT FOR THE DESIGN, DEVELOPMENT, AND ADVANCED CONTINUOUS MANUFACTURING OF PHARMACEUTICAL TABLETS -THE BROADER IMPACT OF THIS SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PHASE II PROJECT IS POTENTIALLY PROFOUND AND COULD OFFER A TRANSFORMATIVE APPROACH TO QUALITY ASSURANCE IN PHARMACEUTICAL MANUFACTURING THAT DIRECTLY TARGETS MEDICINE SUPPLY CHAIN VULNERABILITIES AND COST STRUCTURE IN THE UNITED STATES. IT AIMS TO MODERNIZE THE QUALITY TESTING OF THE MOST WIDELY USED PHARMACEUTICAL DOSAGE FORM?TABLETS?THROUGH RAPID ULTRASONIC TESTING TECHNIQUES AND INNOVATIVE AUTOMATION/ROBOTICS. THIS ADVANCEMENT MAY REDUCE THE RISK OF QUALITY FAILURES, DRUG SHORTAGES, AND RECALLS, ENSURING MORE RELIABLE ACCESS TO ESSENTIAL MEDICATIONS FOR THE PUBLIC. NEARLY 70% OF AMERICANS RELY ON PRESCRIPTION DRUGS, WITH A SIGNIFICANT PORTION OF THESE MEDICATIONS CURRENTLY PRODUCED OVERSEAS. THE PROJECT?S COMMERCIAL IMPACT IS IN ITS POTENTIAL TO REDEFINE QUALITY ASSURANCE PRACTICES IN THE PHARMACEUTICAL INDUSTRY, LEADING TO IMPROVED EFFICIENCY, REDUCED COSTS, AND ENHANCED PRODUCT SAFETY. SUCH IMPROVEMENTS CAN CONTRIBUTE TO NATIONAL HEALTH SECURITY BY REDUCING DEPENDENCE ON UNRELIABLE FOREIGN DRUG MANUFACTURING. ITS SOCIETAL BENEFITS INCLUDE IMPROVED HEALTHCARE OUTCOMES THROUGH MORE DEPENDABLE DRUG AVAILABILITY. FURTHERMORE, THE PROJECT OFFERS SIGNIFICANT EDUCATIONAL BENEFITS, PROVIDING HANDS-ON TRAINING AND RESEARCH OPPORTUNITIES FOR STUDENTS IN ADVANCED MANUFACTURING TECHNOLOGIES. THE PROJECT FOCUSES ON INCLUSIVITY, ATTRACTING UNDERREPRESENTED GROUPS INTO ENGINEERING, AND FOSTERING DIVERSITY IN ADVANCED RESEARCH AND INNOVATION IN PHARMACEUTICAL MANUFACTURING. THE PROPOSED PROJECT AIMS TO ADDRESS THE CRITICAL GAP IN THE PHARMACEUTICAL MANUFACTURING INDUSTRY REGARDING THE OUTDATED QUALITY ASSURANCE METHODS AND EQUIPMENT CURRENTLY EMPLOYED IN PRODUCING COMPRESSED PHARMACEUTICAL TABLETS. THE PRIMARY RESEARCH OBJECTIVES ARE TO DEVELOP AND VALIDATE INNOVATIVE ULTRASONIC QUALITY ASSURANCE AND TESTING EQUIPMENT THAT ENABLES RAPID, NON-DESTRUCTIVE, REAL-TIME RELEASE TESTING OF PHARMACEUTICAL TABLETS. THIS NSF STTR II PROJECT SEEKS TO OVERCOME THE LIMITATIONS OF EXISTING MANUFACTURING AND QUALITY ASSURANCE TECHNOLOGIES BY EMPLOYING NOVEL APPROACHES AND ASSOCIATED MATHEMATICAL MODELING TECHNIQUES, INCLUDING MACHINE LEARNING (ML), TO ANALYZE TABLET MICROSTRUCTURES FOR QUALITY ASSURANCE. THE RESEARCH INVOLVES DETAILED MATHEMATICAL MODELING OF THE INTERACTIONS BETWEEN ULTRASONIC WAVES AND THE VISCOELASTIC PROPERTIES OF TABLET MATERIALS, LEVERAGING BOTH FIRST-PRINCIPLES PHYSICS AND ML-BASED MODELING APPROACHES. THE ANTICIPATED TECHNICAL RESULTS INCLUDE THE DEVELOPMENT OF A RELIABLE, COST-EFFECTIVE SOLUTION FOR THE PHARMACEUTICAL INDUSTRY, ENHANCING THE QUALITY ASSURANCE PROCESS FOR TABLET MANUFACTURING THROUGH IMPROVED ACCURACY, EFFICIENCY, AND SCALABILITY. THE PROJECT REPRESENTS A SIGNIFICANT ADVANCEMENT IN THE FIELD, SUPPORTING THE FDA?S INITIATIVES TOWARDS CONTINUOUS MANUFACTURING, QUALITY BY DESIGN, AND PROCESS ANALYTICAL TECHNOLOGY. THIS AWARD REFLECTS NSF'S STATUTORY MISSION AND HAS BEEN DEEMED WORTHY OF SUPPORT THROUGH EVALUATION USING THE FOUNDATION'S INTELLECTUAL MERIT AND BROADER IMPACTS REVIEW CRITERIA.- SUBAWARDS ARE PLANNED FOR THIS AWARD.
Obligated Amount:
997734.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2021-06-15
Awarding Agency Name:
National Science Foundation
Transaction Description:
STTR PHASE I: ULTRASONIC MEASUREMENT INSTRUMENT FOR PHARMACEUTICAL TABLET DESIGN, DEVELOPMENT, AND CONTINUOUS MANUFACTURING
Obligated Amount:
255962.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00

Trademarks Section

Serial Number:
97447241
Mark:
SONICRELEASE
Status:
ABANDONED - NO STATEMENT OF USE FILED
Mark Type:
SERVICE MARK
Application Filing Date:
2022-06-07
Mark Drawing Type:
Standard character mark
Mark Literal Elements:
SONICRELEASE

Goods And Services

For:
Testing of pharmaceuticals; Testing, inspection or research of pharmaceuticals, cosmetics or foodstuff
International Classes:
042 - Primary Class
Class Status:
Active

Date of last update: 27 Mar 2025

Sources: New York Secretary of State